A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria:

• Completion of the 52-week treatment period in either parent GB43311 or GB44332

Exclusion Criteria:

• Withdrawal of consent and/or premature discontinuation from parent study

• Any permanent discontinuation of study drug in parent study

• Significant non-compliance in the parent study, specifically defined as missingscheduled visits, per investigator's judgment

• Any new diagnosis of asthma according to the Global Initiative for Asthma guidelinesor other accepted guidelines since enrolling in the parent study

• Any new clinically significant pulmonary disease other than COPD (e.g., pulmonaryfibrosis, sarcoidosis, chronic pulmonary embolism or primary pulmonary hypertension,alpha-1-antitrypsin deficiency) since enrolling in the parent study

• Any new unstable cardiac disease, myocardial infarction, or New York HeartAssociation Class III or IV heart failure since enrolling in the parent study